Herpes Simplex and Alzheimer’s—Time to Think Again?
work on herpes simplex virus type 1 (HSV1) and Brian Balin ’s data showing induction of amyloid plaques
Upcoming Webinars
No Upcoming Webinars AvailableALL WEBINARS
151 RESULTS
You searched herpes-simplex-and-alzheimers-time-thinkagain
Sort By:
- Most Recent
- Most Commented
- Most Relevant
The Pathogen Hypothesis
Regarding herpes simplex keratitis (HSK), there was an effect but not statistically significant, and we
Alzheimer Immunotherapy Trial Grounded: Time to Reassess Safety and Vaccine Design
against Alzheimer's and other Neurodegenerative Diseases" Question and Answer session with Blas
Reimagining Alzheimer's Disease—Time for Bright New Ideas?
Jersey, believes that the time has come to reassess what we know about AD, focusing less on amyloid and
The Pathogen Hypothesis—Challenging the Primacy of Genetics in Late-Onset Alzheimer Disease.
environmental influences of the microbial world in chronic diseases of aging cannot be dismissed. Time and
Meet New Players, Histone Deacetylase and Sirtuin—Will They Help the Cell Cycle, DNA Repair, and Gene Expression Break Into Alzheimerology’s Major League?
vivo, and this of course differs greatly from herpes simplex virus (HSV)-mediated overexpression.
Calcium Signaling Deficit in the Origin of Alzheimer's Disease
when Ca2+ signal is reduced, tau will accumulate and at the same time become hyperphosphorylated. 6.
Together at Last, Top Five Biomarkers Model Stages of AD
background in AD biomarker studies, or for those who simply had no time to absorb the 10-page article and its
New Frontier: Developing Outcome Measures for Pre-dementia Trials
Alzheimer Network (DIAN), Alzheimer’s Prevention Initiative (API), and the Anti-Amyloid Treatment in
M1 Receptors Play a Central Role in AD Pathology and Cognition
getting permissions for article listed below. Pat suggested a 20-30 minute talk, and then lots of time for
Collective Thought at Its Best: Let’s Contemplate the Centennial
Auguste D. This is a perfect time to sit back and contemplate the field’s past accomplishments and future
Evolution of AD Trials
Conference on Clinical Trials on Alzheimer's Disease was filled beyond the capacity of its venue,
Resolving Controversies on the Path to AD Therapeutics
and Bart de Strooper titled “The amyloid cascade hypothesis for Alzheimer’s Disease: an appraisal for
Susceptibility Testing and Risk Assessment in Alzheimer Disease
testing and Alzheimer disease: Has the time come? Nature Med, 1998. 5(7): p. 757-759. Abstract 11. Green,
Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD
Carrillo, who directs medical and scientific relations at the Alzheimer’s Association, a funding
Have a topic idea for a webinar? We would love to hear it. Send an email to webinars [at] alzforum [dot] org.